Accuray Reports Fourth Quarter and Fiscal 2020 Financial Results

SUNNYVALE, Calif., Aug. 13, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2020.

Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)

Q4 Fiscal 2020 and Recent Operating Highlights

  • Gross orders of $94.3 million, including 8 orders from China
  • Net revenue of $95.0 million, net loss of $0.8 million, Adjusted EBITDA of $9.3 million
  • Generated $19.2 million of operating cash flow and ended the quarter with $108.6 million of cash and short-term restricted cash
  • Shipped nine Synchrony upgrades

Fiscal Year 2020 Highlights

  • Gross orders increased 10 percent to $377.3 million versus prior fiscal year
  • Ending backlog of $602.7 million, an increase of 22 percent from June 30, 2019
  • Robust demand for Synchrony on Radixact: 56 global orders and 16 total shipments since commercial release
  • Net revenue of $382.9 million, net income of $3.2 million, Adjusted EBITDA grew to $26.8 million from $23.7 million in prior fiscal year
  • GAAP operating income grew to $11.9 million from $0.6 million in prior fiscal year

"Despite the circumstances and the uncertainties associated with the COVID-19 pandemic, we finished fiscal 2020 with a solid performance and grew our gross orders by 10 percent year over year," said Josh Levine, president and chief executive officer of Accuray. "I am proud of the team's execution during the quarter, especially given the challenging operating environment created by the pandemic. We saw strong operating cash flow generation during the quarter and exited the quarter with $108.6 million of cash and short-term restricted cash as we continue to focus on operating efficiencies and working capital management.  We believe that our operational focus, joint venture strategy in China, and continued investments in our value creating R&D pipeline projects, positions Accuray strongly for the future."

Q4 Fiscal 2020 Financial Highlights

Gross product orders totaled $94.3 million for the fourth quarter of fiscal 2020 compared to $97.2 million for the prior fiscal year fourth quarter. Ending order backlog was $602.7 million, approximately 22 percent higher than at the end of the prior fiscal year.

Total revenue was $95.0 million for the fourth quarter of fiscal 2020 compared to $117.4 million for the prior fiscal year fourth quarter. Product revenue totaled $40.4 million compared to $60.6 million for the prior fiscal year fourth quarter, while service revenue totaled $54.6 million compared to $56.8 million for the prior fiscal year fourth quarter.

Total gross profit for the fourth quarter of fiscal 2020 was $39.9 million or approximately 42.0 percent of sales, comprised of product gross margin of 45.0 percent and service gross margin of 39.8 percent. This compares to total gross profit of $45.9 million or 39.1 percent of sales, comprised of product gross margin of 40.7 percent and service gross margin of 37.4 percent for the prior fiscal year fourth quarter.

Net loss was $0.8 million, or $0.01 per share, for the fourth quarter of fiscal 2020, compared to a net loss of $1.4 million, or $0.02 per share, for the prior fiscal year fourth quarter.

Adjusted EBITDA for the fourth quarter of fiscal 2020 was $9.3 million, compared to $8.9 million for the prior fiscal year fourth quarter.

Cash, cash equivalents, and short-term restricted cash were $108.6 million as of June 30, 2020, an increase of $17.0 million from March 31, 2020.

Fiscal Year 2020 Highlights

For the fiscal year ended June 30, 2020, gross product orders totaled $377.3 million, representing growth of 10.2 percent compared to the prior fiscal year period.

Total revenue was $382.9 million for the fiscal year ended June 30, 2020 compared to $418.8 million for the prior fiscal year period. Product revenue totaled $167.3 million compared to $196.7 million for the prior fiscal year period, while service revenue totaled $215.6 million compared to $222.1 million for the prior fiscal year period.

Total gross profit for the year ended June 30, 2020 was $149.9 million or 39.1 percent of sales, comprised of product gross margin of 42.7 percent and service gross margin of 36.4 percent. This compares to total gross profit of $162.7 million or 38.8 percent of sales, comprised of product gross margin of 40.7 percent and service gross margin of 37.2 percent for the prior fiscal year period.

Operating expenses were $138.0 million, a decrease of 14.9 percent compared to $162.1 million for the prior fiscal year period.

Net income was $3.2 million, or $0.04 per share, basic, for the fiscal year ended June 30, 2020, compared to a net loss of $16.4 million, or $0.19 per share, basic, for the prior fiscal year period. Net income included a non-cash, special gain of $13.0 million related to the value of the company's capital contribution to its China joint venture in exchange for the company's 49% equity interest in the joint venture. This gain was recorded as non-operating, other income in the second quarter of fiscal 2020.

Adjusted EBITDA for the fiscal year ended June 30, 2020 was $26.8 million, compared to $23.7 million for the prior fiscal year period.

Financial Guidance

The impact of the COVID-19 pandemic on Accuray's fiscal 2021 results remains uncertain. Given the continued evolution of the COVID-19 pandemic and the uncertainty surrounding its impact on the global economy and the healthcare industry, Accuray believes it is prudent to refrain from providing revenue and adjusted EBITDA guidance for fiscal year 2021. The company is carefully monitoring the pandemic and the impact on its business; however, given the uncertainty regarding the pandemic's spread, duration, and impact, the company is currently unable to predict the extent to which the COVID-19 pandemic will impact its future operations and financial results.

Conference Call Information

Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the fourth quarter and fiscal 2020 as well as recent corporate developments. Conference call dial-in information is as follows:

  • U.S. callers: (877) 270-2148
  • International callers: (412) 902-6510

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the Company's Investor Relations page at www.accuray.com.

In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and available for seven days. The replay telephone number is (877) 344-7529 (USA) or (412) 317-0088 (International), Conference ID:10146316. An archived webcast will also be available at Accuray's website until Accuray announces its results for the first quarter of fiscal 2021.

Use of Non-GAAP Financial Measures

Accuray has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation ("adjusted EBITDA").  The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items, including the non-cash, special gain related to Accuray's capital contribution to the China joint venture, an accounts receivable impairment charge, costs associated with reduction of staff and a non-cash reversal of deferred rent related to a lease termination. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results.  A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.

There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures.  Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.

About Accuray

Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and sells radiotherapy systems that are intended to make cancer treatments shorter, safer, personalized and more effective, ultimately enabling patients to live longer, better lives. Our radiation treatment delivery systems in combination with fully-integrated software solutions set the industry standard for precision and cover the full range of radiation therapy and radiosurgery procedures. For more information, please visit www.accuray.com.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations; expectations regarding the effect of the COVID-19 pandemic on the company and the company's position after the pandemic; the company's ability to realize the benefits of its operational focus, joint venture strategy in China, and continued investments in R&D pipeline projects; the company's ability to capitalize on operating efficiencies and working capital management; expectations regarding future sales in China; expectations regarding our Chinese joint venture, including the timing of revenue recognition and the manufacture and shipment of a joint venture manufactured product; expectations regarding the company's product portfolio, including with respect to the company's new Synchrony upgrade; expectations regarding the future of radiotherapy treatment; and the company's leadership position in radiation oncology innovation and technologies.  These forward-looking statements involve risks and uncertainties.  If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements.  These risks and uncertainties include, but are not limited to, the effect of the COVID-19 pandemic on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products, including new product and software offerings; the company's ability to develop new products or enhance existing products to meet customers' needs and compete favorably in the market, the company's ability to effectively integrate and execute the joint venture, the company's ability to realize the expected benefits of the joint venture; the ability of customers in China to obtain Class or B user licenses to purchase radiotherapy systems; risks inherent in international operations, the company's ability to effectively manage its growth, the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on May 8, 2020 and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events.  The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Financial Tables to Follow

Accuray Incorporated

Consolidated Statements of Operations

(in thousands, except per share data)

(Unaudited)




Three Months Ended

June 30,



Twelve Months Ended

June 30,




2020



2019



2020



2019


Gross Orders


$

94,293



$

97,166



$

377,295



$

342,321


Net Orders



74,607




64,364




280,144




218,263


Order Backlog



602,713




495,627




602,713




495,627


Net revenue:

















Products


$

40,410



$

60,646



$

167,302



$

196,665


Services



54,567




56,771




215,626




222,120


Total net revenue



94,977




117,417




382,928




418,785


Cost of revenue:

















Cost of products



22,221




35,956




95,882




116,711


Cost of services



32,860




35,535




137,174




139,423


Total cost of revenue



55,081




71,491




233,056




256,134


Gross profit



39,896




45,926




149,872




162,651


Operating expenses:

















Research and development



12,215




16,051




49,784




56,493


Selling and marketing



11,555




14,920




47,254




55,998


General and administrative



11,570




11,697




40,966




49,577


Total operating expenses



35,340




42,668




138,004




162,068


Income from operations



4,556




3,258




11,868




583


Loss on equity investment, net



(371)







(149)





Other expense, net



(4,746)




(3,794)




(6,700)




(14,927)


Income (loss) before provision for income taxes



(561)




(536)




5,019




(14,344)


Provision for income taxes



262




864




1,863




2,086


Net income (loss)


$

(823)



$

(1,400)



$

3,156



$

(16,430)


Net income (loss) per share - basic


$

(0.01)



$

(0.02)



$

0.04



$

(0.19)


Net income (loss) per share - diluted


$

(0.01)



$

(0.02)



$

0.03



$

(0.19)


Weighted average common shares used in

   computing income (loss) per share:

















Basic



90,748




88,202




89,874




87,465


Diluted



90,748




88,202




90,623




87,465


 

Accuray Incorporated

Consolidated Balance Sheets

(in thousands)

(Unaudited)




June 30,



June 30,




2020



2019


Assets









Current assets:









Cash and cash equivalents


$

107,577



$

76,798


Restricted cash



997




10,218


Accounts receivable, net



89,599




111,885


Inventories



134,525




120,823


Prepaid expenses and other current assets



21,227




24,205


Deferred cost of revenue



2,712




146


Total current assets



356,637




344,075


Property and equipment, net



15,349




17,122


Investment in joint venture



13,929





Goodwill



57,717




57,770


Intangible assets, net



663




679


Operating lease right-of-use assets



28,647





Other assets



17,136




18,535


Total assets


$

490,078



$

438,181


Liabilities and equity









Current liabilities:









Accounts payable


$

23,126



$

29,562


Accrued compensation



17,963




31,150


Operating lease liabilities, current



8,224





Other accrued liabilities



27,180




32,742


Customer advances



22,571




20,395


Deferred revenue



83,207




78,332


Total current liabilities



182,271




192,181


Long-term other liabilities



7,416




9,646


Deferred revenue



24,125




26,639


Operating lease liabilities, non-current



24,173





Long-term debt



189,307




159,844


Total liabilities



427,292




388,310


Equity:









Common stock



91




89


Additional paid-in capital



545,741




535,332


Accumulated other comprehensive loss



(662)




(10)


Accumulated deficit



(482,384)




(485,540)


Total equity



62,786




49,871


Total liabilities and equity


$

490,078



$

438,181


 

Accuray Incorporated

Reconciliation of GAAP Net Loss to Adjusted Earnings Before Interest, Taxes, Depreciation,

Amortization and Stock-Based Compensation (Adjusted EBITDA)

(in thousands)

(Unaudited)




Three Months Ended

June 30,



Twelve Months Ended

June 30,




2020



2019



2020



2019


GAAP net income (loss)


$

(823)



$

(1,400)



$

3,156



$

(16,430)


Depreciation and amortization



1,960




2,178




7,526




8,266


Stock-based compensation



2,287




2,822




8,152




10,601


Interest expense, net



4,590




3,973




17,986




15,015


Gain on contribution to equity method investment in joint
venture (a)









(12,965)





Impairment charge (b)












3,707


Cost savings initiative (c)



1,058




511




1,058




1,509


Gain on lease termination (d)












(1,007)


Provision for income taxes



262




864




1,863




2,086


Adjusted EBITDA


$

9,334



$

8,948



$

26,776



$

23,747


____________________

(a) consists of non-cash gain related to the value of the Company's capital contribution to the China joint venture.

(b) consists of an accounts receivable impairment charge related to one customer in the first quarter of 2019.

(c) consists of costs associated with reduction of staff.

(d) consists of a non-cash reversal of deferred rent related to a facility lease that was terminated.

 

Joe Diaz

Beth Kaplan

Investor Relations, Lytham Partners

Public Relations Director, Accuray

+1 (602) 889-9700

+1 (408) 789-4426

diaz@lythampartners.com

bkaplan@accuray.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/accuray-reports-fourth-quarter-and-fiscal-2020-financial-results-301111995.html

SOURCE Accuray Incorporated

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.